Medinice S.A Cash Flow Conversion Efficiency
Medinice S.A cash flow conversion efficiency. Based on the latest financial reports, Medinice S.A (ICE) has a cash flow conversion efficiency ratio of -0.020x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-1.77 Million ≈ $-487.13K USD) by net assets (zł88.12 Million ≈ $24.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Medinice S.A (2016–2025)
Cash flow conversion efficiency of Medinice S.A from 2016 to 2025. This chart illustrates how Medinice S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Medinice S.A stock quote for real-time trading data and today's change.
Medinice S.A Cash Flow Conversion Ratio Explained
Medinice S.A cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Medinice S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medinice S.A ranked by their cash flow conversion efficiency. Also see ICE company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GREENLAND RESOURCES INC.
F:M0LY
|
-0.139x |
|
Hsin Kao Gas Co Ltd
TW:9931
|
0.037x |
|
FIT Holding Co Ltd
TW:3712
|
0.259x |
|
AMPACS Corp.
TW:6743
|
0.174x |
|
Calin Technology Co Ltd
TW:4976
|
-0.039x |
|
Soc Centrale Bois Scieries Manche SA
PA:CBSM
|
0.037x |
|
S&P Syndicate Public Company Limited
BK:SNP
|
0.106x |
|
Tera Autotech
TWO:6234
|
0.013x |
Annual Cash Flow Conversion Efficiency for Medinice S.A (2016–2025)
The table below shows the annual cash flow conversion efficiency of Medinice S.A from 2016 to 2025. Review ICE FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | zł88.12 Million ≈ $24.25 Million |
zł-5.58 Million ≈ $-1.54 Million |
-0.063x | -40.47% |
| 2024-12-31 | zł81.01 Million ≈ $22.30 Million |
zł-3.65 Million ≈ $-1.01 Million |
-0.045x | +56.60% |
| 2023-12-31 | zł33.17 Million ≈ $9.13 Million |
zł-3.45 Million ≈ $-948.66K |
-0.104x | -38.40% |
| 2022-12-31 | zł37.13 Million ≈ $10.22 Million |
zł-2.79 Million ≈ $-767.30K |
-0.075x | -81.17% |
| 2021-12-31 | zł40.58 Million ≈ $11.17 Million |
zł-1.68 Million ≈ $-462.91K |
-0.041x | +78.44% |
| 2020-12-31 | zł16.98 Million ≈ $4.67 Million |
zł-3.26 Million ≈ $-898.30K |
-0.192x | +69.21% |
| 2019-12-31 | zł8.23 Million ≈ $2.26 Million |
zł-5.14 Million ≈ $-1.41 Million |
-0.624x | +3.90% |
| 2018-12-31 | zł2.92 Million ≈ $802.27K |
zł-1.89 Million ≈ $-521.27K |
-0.650x | -25.07% |
| 2017-12-31 | zł3.26 Million ≈ $898.55K |
zł-1.70 Million ≈ $-466.80K |
-0.520x | +87.38% |
| 2016-12-31 | zł151.95K ≈ $41.82K |
zł-625.36K ≈ $-172.11K |
-4.116x | -- |
About Medinice S.A
Medinice S.A., a medical technology company, creates, develops, and commercializes minimally invasive solutions in cardiology and cardiac surgery. The company offers PacePress, a medical device to reduce the risk of complications following the implantation of cardiac electrotherapeutic devices, such as pacemakers or implantable cardioverter-defibrillators; CoolCryo, a cardiac cryoablation technol… Read more